TABLE 2.
Use of Medication During First Year of Treatment for Patients With First-Episode Core Schizophrenia, Divided by Remission Status at 1-Year Follow-up
| Remitted (n = 25) | Nonremitted (n = 53) | P | |
|---|---|---|---|
| Total duration of antipsychotic treatment, mean (SD), wk | n = 22 | n = 51 | 0.196 |
| 41.5 (15.7) | 33.9 (20.2) | ||
| No. periods with antipsychotic treatment, n (SD) | n = 25 | n = 53 | 0.481 |
| 1.32 (0.8) | 1.5 (1.05) | ||
| No. antipsychotics used, n (%) | n = 25 | n = 53 | |
| 1 | 17 (68) | 30 (56.6) | |
| 2 | 4 (16) | 8 (15.1) | |
| 3 | 2 (8) | 9 (17) | |
| 4 | 0 (0) | 2 (3.8) | |
| No use | 2 (8) | 4 (7.5) | 0.255* |
| First antipsychotic of choice, n (%) | n = 23 | n = 49 | |
| Olanzapine | 11 (47.8) | 22 (44.9) | |
| Risperidone | 4 (17.4) | 8 (16.3) | |
| Quetiapine | 3 (13) | 8 (16.3) | |
| Aripiprazole | 3 (13) | 2 (4.1) | |
| Ziprazidone | 2 (8.7) | 4 (8.2) | |
| Perphenazine | 0 | 2 (4.1) | |
| Haloperidol | 0 | 1 (2.0) | |
| Chlorpromazine | 0 | 1 (2.0) | |
| Amisulpride | 0 | 1 (2.0) | |
| Second antipsychotic of choice, n | n = 6 | n = 19 | |
| Risperidone | 1 | 5 | |
| Aripiprazole | 2 | 5 | |
| Olanzapine | 3 | 2 | |
| Amisulpride | 0 | 2 | |
| Haloperidol | 0 | 2 | |
| Ziprazidone | 0 | 1 | |
| Quetiapine | 0 | 1 | |
| Clozapine | 0 | 1 | |
| Third antipsychotic of choice, n | n = 2 | n = 11 | |
| Quetiapine | 0 | 3 | |
| Risperidone | 0 | 2 | |
| Olanzapine | 0 | 1 | |
| Ziprazidone | 1 | 2 | |
| Aripiprazole | 1 | 1 | |
| Perphenazine | 0 | 1 | |
| Levomepromazine | 0 | 1 | |
| Fourth antipsychotic of choice, n | n = 0 | n = 2 | |
| Risperidone | 0 | 1 | |
| Clozapine | 0 | 1 |
*χ2 calculated from no use, use of 1 antipsychotic, and use of more than 1 antipsychotic.